Search

Author/Creator Sherif, Bintu

2. Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. (4th December 2022)

Authors:
Taylor, Matthew H.; Leboulleux, Sophie; Panaseykin, Yury; Konda, Bhavana; de La Fouchardiere, Christelle; Hughes, Brett G. M.; Gianoukakis, Andrew G.; Park, Young Joo; Romanov, Ilia; Krzyzanowska, Monika K.; Garbinsky, Diana; Sherif, Bintu; Pan, Jie Janice; Binder, Terri A.; Sauter, Nicholas; Xie...
Journal:
Cancer medicine
Issue:
Volume 12:Number 4(2023)
Page Start:
4332
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2‐Year Results From a Multicenter, Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled Phase III Study. Issue 10 (1st September 2018)

Authors:
Coates, Laura C.; Mease, Philip J.; Gossec, Laure; Kirkham, Bruce; Sherif, Bintu; Gaillez, Corine; Mpofu, Shephard; Jugl, Steffen M.; Karyekar, Chetan; Gandhi, Kunal K.
Journal:
Arthritis care & research
Issue:
Volume 70:Issue 10(2018)
Page Start:
1529
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study. (April 2023)

Authors:
Wolf, Jürgen; Garon, Edward B.; Groen, Harry J.M.; Tan, Daniel S.W.; Gilloteau, Isabelle; Le Mouhaer, Sylvie; Hampe, Marcio; Cai, Can; Chassot-Agostinho, Andrea; Reynolds, Maria; Sherif, Bintu; Heist, Rebecca S.
Journal:
European journal of cancer
Issue:
Volume 183(2023)
Page Start:
98
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab. (18th August 2017)

Authors:
Elewski, Boni E.; Puig, Lluís; Mordin, Margaret; Gilloteau, Isabelle; Sherif, Bintu; Fox, Todd; Gnanasakthy, Ari; Papavassilis, Charis; Strober, Bruce E.
Journal:
Journal of dermatological treatment
Issue:
Volume 28:Number 6(2017)
Page Start:
492
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2. (23rd November 2015)

Authors:
Fernandez, Maria M; Wang, Jianmin; Ye, Xin; Kwong, Winghan Jacqueline; Sherif, Bintu; Hogue, Susan; Sherrill, Beth
Journal:
SAGE open medicine
Issue:
Volume 3(2015)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. (March 2022)

Authors:
Strand, Vibeke; Kaeley, Gurjit S; Bergman, Martin J; Gladman, Dafna D; Coates, Laura C; Sherif, Bintu; Hur, Peter; Parikh, Bhumik; Gilloteau, Isabelle; Mease, Philip J
Journal:
Lancet
Issue:
Volume 4:Number 3(2022)
Page Start:
e208
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗